Singapore-based firm on track to commercialise cancer drug
Tessa Therapeutics teams up with California institute to run cancer-therapy trial, commercial launch expected in 2020
Add BT as a preferred source
Singapore
SCIENTISTS are now a step closer to turning cancer patients' own immune cells (T-cells) against the tumours in their bodies - and possibly finding a cure for the dreaded disease.
A Singapore-based biotechnology firm has emerged ahead of the very crowded research field of T-cell immunotherapy, by conducting the world's first US Food and Drug Administration (FDA) Phase Three cancer T-cell therapy trial involving a number of hospitals and treatment centres across the world.
TRENDING NOW
‘I felt like dying’: Thai Singha beer scion speaks up after disclosure of alleged sexual abuse
CSE Global independent director quits after clashes with chairman Eugene Lai over board refresh
Tiger Beer lines up new products as Singapore operations’ role shifts from brewing to innovation
Single founders, billion-dollar valuations: AI is minting unicorn startups at birth
